What is the latest YATHARTH stock price?
The latest stored price for YATHARTH is Rs 848.90 as of 2026-07-20.
YATHARTH HOSP & TRA C S L is a small-cap stock in Healthcare. This Gimli page shows the latest available YATHARTH price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
The latest stored price for YATHARTH is Rs 848.90 as of 2026-07-20.
YATHARTH is above 50DMA, above 200DMA. The latest 50DMA is 834.19 and the latest 200DMA is 743.85.
YATHARTH has PE 46.43, ROE +10.23%, and ROCE +12.32% in Gimli's latest available snapshot.
YATHARTH has returned +1.09% over 1 month, +14.14% over 3 months, and +35.65% over 12 months in the latest stored data.
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 341.56 cr | 87.02 cr | 47.52 cr | 4.93 |
| 2025-12-31 | 320.47 cr | 82.07 cr | 45.35 cr | 4.71 |
| 2025-09-30 | 279.42 cr | 74.01 cr | 41.24 cr | 4.28 |
| 2025-06-30 | 257.77 cr | 73.80 cr | 42.04 cr | 4.36 |
| 2025-03-31 | 233.03 cr | 62.37 cr | 38.72 cr | 4.37 |
| 2024-12-31 | 219.16 cr | 59.13 cr | n/a | nan |
| 2024-09-30 | 217.77 cr | 57.60 cr | n/a | 3.61 |
| 2024-06-30 | 211.78 cr | 57.32 cr | 30.38 cr | 3.54 |
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 1,207.17 cr | 317.90 cr | 175.38 cr | nan |
| 2025-03-31 | 885.62 cr | 236.42 cr | 130.54 cr | 14.72 |
| 2024-03-31 | 670.55 cr | 195.55 cr | 114.47 cr | 14.46 |
| 2023-03-31 | 520.29 cr | 136.57 cr | 65.77 cr | 7.66 |
| 2022-03-31 | 299.86 cr | 112.46 cr | 42.09 cr | 5.14 |
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 2,281.53 cr | 221.10 cr | 264.09 cr | 1,807.16 cr |
| 2025-03-31 | 1,731.18 cr | 204.96 cr | 11.59 cr | 1,637.13 cr |
| 2024-03-31 | 1,019.33 cr | 81.40 cr | 84.65 cr | 874.32 cr |
| 2023-03-31 | 485.97 cr | 37.23 cr | 267.41 cr | 182.96 cr |
| 2022-03-31 | 426.02 cr | 11.66 cr | 263.78 cr | 116.89 cr |
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 204.52 cr | -112.02 cr | n/a |
| 2025-03-31 | 131.17 cr | -170.75 cr | n/a |
| 2024-03-31 | -3.08 cr | -96.44 cr | n/a |
| 2023-03-31 | 63.78 cr | 43.97 cr | n/a |
| 2022-03-31 | 59.94 cr | 46.80 cr | n/a |
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-03-31 | +55.80% | +5.25% | +12.00% | +9.37% | +26.95% | +10.73% |
| 2025-12-31 | +55.80% | +6.18% | +11.01% | +9.19% | +27.01% | +10.73% |
| 2025-09-30 | +61.64% | +6.50% | +8.70% | +7.12% | +23.16% | +15.33% |
| 2025-06-30 | +61.64% | +4.34% | +13.52% | +9.43% | +20.50% | +13.81% |
| 2025-03-31 | +61.64% | +4.45% | +13.56% | +9.42% | +20.35% | +13.81% |
| 2024-12-31 | +61.44% | +9.78% | +11.50% | +7.32% | +17.28% | +0.00% |
| 2024-09-30 | +66.54% | +6.28% | +6.98% | +3.70% | +20.20% | +0.00% |
| 2024-06-30 | +66.54% | +4.89% | +9.41% | +3.91% | +19.16% | +0.00% |
| 2024-03-31 | +66.54% | +3.99% | +9.33% | +3.55% | +20.13% | +0.00% |
| 2023-12-31 | +66.44% | +2.59% | +8.81% | +3.49% | +22.15% | +0.18% |
| 2023-09-30 | +66.33% | +5.42% | +9.07% | +2.94% | +19.18% | n/a |
| 2023-08-02 | +66.33% | +4.25% | +9.07% | +3.39% | +20.34% | +0.00% |
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 469,405.90 cr | 40.823336 | +14.71% | +15.52% |
| DIVISLAB | DIVI S LABORATORIES LTD | 194,269.92 cr | 75.650281 | +16.19% | +8.71% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 169,405.46 cr | 78.319677 | +17.18% | +42.14% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 128,040.28 cr | 65.380043 | +21.03% | +21.93% |
| CIPLA | CIPLA LTD | 116,452.52 cr | 30.005339 | +11.79% | -2.75% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 115,616.29 cr | 23.056854 | +17.93% | +17.85% |
| LUPIN | LUPIN LIMITED | 113,320.96 cr | 21.221472 | +26.83% | +28.27% |
| MAXHEALTH | MAX HEALTHCARE INS LTD | 107,290.40 cr | 74.382732 | +14.33% | -9.32% |
Data snapshot: 2026-07-20. Not investment advice.